Trials / Completed
CompletedNCT01539577
A Long-Term Safety Study of OZURDEX® in Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 875 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or patients with non-infectious posterior segment uveitis in real-world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone 700 μg intravitreal implant | dexamethasone 700 μg intravitreal implant administered according to general clinical practice. |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2012-02-27
- Last updated
- 2016-04-20
Locations
4 sites across 4 countries: France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01539577. Inclusion in this directory is not an endorsement.